Evidence map›Paper›PMID 29951886›Full record

Trial reportSleep & breathing = Schlaf & Atmung2019

Metoprolol has a similar therapeutic effect as amlodipine on BP lowering in hypertensive patients with obstructive sleep apnea.

Jing Shi, Yue Yuan, Xianzhu Deng, Yujiao Pan, Meijiao He, Guangzhong Liu, Danghui Sun, Jiayu Wang, Wennan Wang, Yue Li

Abstract readComparative StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Sleep & breathing = Schlaf & Atmung, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Management of hypertension in obstructive sleep apnea.American journal of preventive cardiology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Jing ShiCardiovascular Department, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Yue YuanCardiovascular Department, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Xianzhu DengCardiovascular Department, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Yujiao PanCardiovascular Department, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Meijiao HeCardiovascular Department, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Guangzhong LiuCardiovascular Department, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Danghui SunCardiovascular Department, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Jiayu WangCardiovascular Department, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Wennan WangCardiovascular Department, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Yue LiCardiovascular Department, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China. ly99ly@vip.163.com.ORCID http://orcid.org/0000-0002-7727-905X
Harbin Medical University · CN

Funding

Chang Jiang Scholar Candidates Programme for Provincial Universities in Heilongjiang 2013CJHB001Heilongjiang Province Outstanding Youth Foundation JC201208National Basic Research Program of China 2014CB542401National Natural Science Foundation of China 81470462National Natural Science Foundation of China 81670297the Technology Research and Development Program of Heilongjiang Province GA14C101
6 · The paper itself

Abstract

purposeβ-Blocker use has been controversial for a long time in the management of hypertensive patients with obstructive sleep apnea (OSA). The aim of present study was to compare the effects of metoprolol on BP lowering with amlodipine in hypertensive OSA patients.

methodsHypertensive subjects with OSA were randomly assigned to metoprolol and amlodipine groups, receiving 12 weeks of oral either metoprolol (47.5 mg once daily) or amlodipine (5 mg once daily) treatment. At baseline and after the 12-week treatment period, 24-h ambulatory blood pressure monitoring was performed in both groups.

resultsBoth of metoprolol and amlodipine treatments significantly lowered 24-h blood pressure (BP) (from 143/88 to 132.3/81.6 mmHg; from 141.3/84.5 to 133.7/80.8 mmHg), daytime BP (from 146/90.2 to 136.4/84.6 mmHg; from 145.1/87.6 to 138.2/84.1 mmHg), and nighttime BP (from 139.1/83.9 to 125.7/76.2 mmHg; from 134.5/78.5 to 125.8/74.1 mmHg) (all P < 0.05). But there were no significant differences between the groups in BP variability (P > 0.05). Besides, metoprolol significantly reduced daytime heart rate (HR) (P < 0.05), while 24-h and nighttime HR values had no remarkable changes compared with baseline (P > 0.05).

conclusionsMetoprolol had similar therapeutic effects on BP lowering as amlodipine and could not decrease HR during the nighttime in hypertensive patients with OSA.

Indexed as

Administration, OralAdultAgedAmlodipineBlood PressureBlood Pressure Monitoring, AmbulatoryCohort StudiesComorbidityFemaleHeart RateHumansHypertensionMaleMetoprololMiddle AgedPolysomnographyAmlodipineMetoprololBlood pressureCalcium channel blockersHypertensionObstructive sleep apneaβ1-Blockers

Identifiers

PMID29951886
OpenAlexW2809743655

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.